Additionally, in the ATTACH (Anti-Tnf alpha Therapy Against Chronic Heart failure) short-term trial, TNFα antagonism using infliximab did not ameliorate, and high doses increased the risk of HF-related hospitalization or death of patients affected by moderate-to-severe chronic HF [143]. The gene discussed is TNF; the disease is congestive heart failure.